Abstract: A livestock shed for keeping livestock animals includes a shed building for keeping the livestock animals, having a floor which is at least partially permeable to excretory products from the livestock animals, a liquid-tight manure cellar for collecting excretory products which is situated at least partly under the floor, and an air scrubber connected to the manure cellar and configured to at least partly clean polluted manure cellar air. The air scrubber is provided directly above the manure cellar.

Abstract: In an assembly of a living surface for a farm mammal, in particular cattle, and a processing device for processing urine from the farm mammal, the living surface is configured to catch the excretory products including feces and urine from the farm mammal, wherein the assembly includes a urine removal device for removing urine essentially separately from feces and draining the urine from the living surface in a urine-rich stream, and is configured to feed the urine-rich stream to the processing device, and wherein the processing device includes a nitrogen removal device for removing nitrogenous substances from the urine-rich stream.

Abstract: The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.

Abstract: The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.

Abstract: A pharmaceutical composition comprising N-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, wherein at least some of the SB 207266 or salt thereof is in granulated form. Preferably, a filler and/or binder are also present.

Abstract: A pharmaceutical composition for administration to the skin, which comprises [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo[2.2.2]oct-3-yl)acentonitrile or a pharmaceutically acceptable salt thereof together with a suitable pharmaceutically acceptable carrier, for the treatment or prophylaxis of dementia.

Abstract: Aqueous multiphase dispersions for multicolor coatings are produced by a process essentially comprising the steps of:providing one or more emulsion paints;adding at least one linear colloid capable of being insolubilised by borate ions and at least one hydrophilic inorganic clay to said paints to form base paints;providing an aqueous medium containing at least one hydrophilic inorganic clay;adding said base paints into said aqueous medium;adding borate ions to said aqueous medium;adding at least one emulsified binder to said medium;each of the emulsion paints having a different color.It is preferred to use galactomannoglycans as colloid (most preferably guar gum) and synthetic clays (most preferably of the smectite or hectorite types).